FBLG Stock Overview
Operates as a cell therapy, regenerative medicine company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
FibroBiologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.58 |
| 52 Week High | US$55.00 |
| 52 Week Low | US$1.08 |
| Beta | 0 |
| 11 Month Change | -23.89% |
| 3 Month Change | 101.56% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.13% |
Recent News & Updates
Shareholder Returns
| FBLG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -30.6% | -10.8% | -2.1% |
| 1Y | n/a | 13.9% | 30.2% |
Return vs Industry: Insufficient data to determine how FBLG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FBLG performed against the US Market.
Price Volatility
| FBLG volatility | |
|---|---|
| FBLG Average Weekly Movement | 23.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FBLG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FBLG's weekly volatility has decreased from 29% to 23% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 10 | Pete O’Heeron | www.fibrobiologics.com |
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. Fundamentals Summary
| FBLG fundamental statistics | |
|---|---|
| Market cap | US$89.42m |
| Earnings (TTM) | -US$17.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs FBLG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBLG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.78m |
| Earnings | -US$17.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.2% |
How did FBLG perform over the long term?
See historical performance and comparison